Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Treatment sequencing for metastatic castration-resistant prostate cancer

Mark Christopher Markowski • 5 Jun 2022
ASCO 2022
Genitourinary Cancer Prostate Cancer 177Lu-PSMA-617

Mark Christopher Markowski, MD, PhD, Johns Hopkins Medicine, Baltimore, MD, discusses treatment sequencing for metastatic castration-resistant prostate cancer (mCRPC), which still remains to be determined, particularly with the introduction of newer experimental compounds such as lutetium PSMA. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Mark Christopher Markowski

0:58
Sabizabulin in men with mCRPC who progressed on an androgen receptor targeting agent
Mark Christopher Markowski • 5 Jun 2022
0:28
177Lu-PSMA-617 for metastatic castration-resistant prostate cancer
Mark Christopher Markowski • 5 Jun 2022
0:53
OS and biomarker results from COMBAT: bipolar androgen therapy plus nivo for patients with mCRPC
Mark Christopher Markowski • 5 Jun 2022

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals